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PUK17 ESTIMATING THE QUALITY OF LIFE IMPACTS OF

PUK19 PSYCHOMETRIC EVALUATION OF THE KHQ IN TEN LANGUAGES
METHODS:
The KHQ, a 21-item instrument to assess healthrelated quality of life in patients with urinary incontinence and OAB, has been translated into numerous languages. Data from a multicenter, randomized, double-blind, placebo-and activecontrolled trial of fesoterodine for OAB patients were analyzed to assess the psychometric properties of the KHQ in ten languages. Patients completed the KHQ at Baseline (BL) and Week 12 of treatment and bladder diaries for 3 days before each visit. Mean BL scores, Cronbach alphas, and subscale change scores were calculated for the KHQ in each language. RESULTS: Data from 839 patients were analyzed (Australia = 104; Bulgaria = 58; Czech Republic = 55; Estonia = 59; Germany = 59; New Zealand (NZ) = 82; Poland = 84; Romania = 66; Russia = 81; and South Africa = 191). Mean age was 56.7 Ϯ 13.9 years; 80% were female; 96% were white. BL subscale scores ranged from 16.8 (General Health Perceptions [GHP] ; NZ English) to 83.6 (Impact on Life; German). Six of 7 multi-item KHQ subscales (Role Abstracts A655
